MYCN Reprograms Neuroblastoma Metabolism
[Technical Report, Annual Report]
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
Despite current aggressive regimens, the majority of patients with MYCN amplification die due to drug-resistant disease, and further intensification of chemotherapy will not significantly improve this outcome. We propose an entirely novel strategy to oppose MYCN oncogenic function in NB by blocking the metabolic reprogramming driven by MYCN. Our guiding hypothesis is that lipid metabolism is required for NB tumorigenesis. We have shown that lipid metabolism is a selective metabolic dependency of MYCN-induced tumors. Targeting MYCN-driven lipogenesis effectively blocks in vivo tumor growth in multiple models of NB and sensitize NB tumors to conventional chemotherapy.
- Medicine and Medical Research